Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases

British Journal of Cancer

Volumn 115, Issue 11, 2016, Pages 1391-1399

  Shafrir, Amy L ^a,b   Babic, Ana ^b   Tamimi, Rulla M ^a,b   Rosner, Bernard A ^a,b   Tworoger, Shelley S ^a,b   Terry, Kathryn L ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CISPLATIN DERIVATIVE; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; ANTINEOPLASTIC AGENT; PLATINUM;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; MENSTRUAL IRREGULARITY; MIDDLE AGED; ORAL CONTRACEPTIVE USE; OVARY CARCINOMA; OVERALL SURVIVAL; PARITY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; REPRODUCTION; SPONTANEOUS ABORTION; TREATMENT DURATION; UNITED STATES; UTERINE TUBE LIGATION; DRUG RESISTANCE; OVARIAN NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL ANALYSIS; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MENARCHE; MENOPAUSE; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84990216889     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.316     Document Type: Article

References (36)

1. Anuradha S, Webb PM, Blomfield P, Brand AH, Friedlander M, Leung Y, Obermair A, Oehler MK, Quinn M, Steer C, Jordan SJ (2014) Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. Med J Aust 201(5): 283-288.
2. Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE (2000) Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab 85(8): 2897-2902.
3. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR, Seamon LG (2012) Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 120(3): 612-618.
4. Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Collaborative Group On Epidemiological Studies Of Ovarian Cancer (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385(9980): 1835-1842.
5. Besevic J, Gunter MJ, Fortner RT, Tsilidis KK, Weiderpass E, Charlotte Onland-Moret N, Dossus L, Tjonneland A, Hansen L, Overvad K, Mesrine S, Baglietto L, Clavel-Chapelon F, Kaaks R, Aleksandrova K, Boeing H, Trichopoulou A, Lagiou P, Bamia C, Masala G, Agnoli C, Tumino R, Ricceri F, Panico S, Bueno-de-Mesquita HA, Peeters PH, Jareid M, Ramon Quiros J, Duell EJ, Sanchez MJ, Larranaga N, Chirlaque MD, Barricarte A, Dias JA, Sonestedt E, Idahl A, Lundin E, Wareham NJ, Khaw KT, Travis RC, Rinaldi S, Romieu I, Riboli E, Merritt MA (2015) Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study. Br J Cancer 113(11): 1622-1631.
6. Christante D, Pommier S, Garreau J, Muller P, LaFleur B, Pommier R (2008) Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up. Am J Surg 196(4): 505-511.
7. Felix AS, Bunch K, Yang HP, Arem H, Trabert B, Gierach GL, Park Y, Lowery WJ, Brinton LA (2015) Menopausal hormone therapy and mortality among women diagnosed with ovarian cancer in the NIH-AARP Diet and Health Study. Gynecol Oncol Rep 13: 13-17.
8. Garrett LA, GrowdonWB, Goodman A, Boruta DM, Schorge JO, del CarmenMG (2013) Endometriosis-associated ovarian malignancy: a retrospective analysis of presentation, treatment, and outcome. J Reprod Med 58(11-12): 469-476.
9. Gazvani R, Templeton A (2002) Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 123: 217-226.
10. Hecht JL, Kotsopoulos J, Hankinson SE, Tworoger SS (2009) Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev 18(5): 1624-1630.
11. Hein A, Thiel FC, Bayer CM, Fasching PA, Haberle L, Lux MP, Renner SP, Jud SM, Schrauder MG, Muller A, Wachter D, Strehl J, Hartmann A, Beckmann MW, Rauh C (2013) Hormone replacement therapy and prognosis in ovarian cancer patients. Eur J Cancer Prev 22(1): 52-58.
12. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KAe (2015) SEER Cancer Statistics Review, 1975-2012. National Cancer Institute: Bethesda, MD, USA, Available at http://seer. cancer.gov/csr/1975-2012/based on November 2014 SEER data submission, posted to the SEER web site in April 2015.
13. Jacobsen BK, Vollset SE, Kvale G (1993) Reproductive factors and survival from ovarian cancer. Int J Cancer 54: 904-906.
14. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 384: 1376-1388.
15. Kim HS, Kim TH, Chung HH, Song YS (2014) Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer 110(7): 1878-1890.
16. Kjaerbye-Thygesen A, Frederiksen K, Hogdall EV, Glud E, Christensen L, Hogdall CK, Blaakaer J, Kjaer SK (2006) Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 15(4): 798-803.
17. Markman M, Bookman MA (2000) Second-line treatment of ovarian cancer. Oncologist 5: 26-35.
18. Mascarenhas C, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I, Weiderpass E (2006) Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 119(12): 2907-2915.
19. Melin A, Lundholm C, Malki N, Swahn ML, Sparen P, Bergqvist A (2011) Endometriosis as a prognostic factor for cancer survival. Int J Cancer 129(4): 948-955.
20. Nagle CM, Bain CJ, Green AC, Webb PM (2008) The influence of reproductive and hormonal factors on ovarian cancer survival. Int J Gynecol Cancer 18(3): 407-413.
21. Naik R, Nordin A, Cross PA, Hemming D, de Barros Lopes A, Monaghan JM (2000) Risk factors in stage III epithelial ovarian cancer: previous sterilisation is an adverse independent prognostic indicator. Eur J Gynaecol Oncol 21(4): 357-361.
22. NCI (2015) Recurrent or persistent ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment. In Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment-for health professionals (PDQ). National Institutes of Health: Bethesda, MD, USA.
23. Noli S, Cipriani S, Scarfone G, Villa A, Grossi E, Monti E, Vercellini P, Parazzini F (2013) Long term survival of ovarian endometriosis associated clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer 23(2): 244-248.
24. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13(4): 385-394.
25. Poole EM, Konstantinopoulos PA, Terry KL (2016) Prognostic implications of reproductive and lifestyle factors in ovarian cancer. Gynecol Oncol 142: 574-587.
26. Poole EM, Merritt MA, Jordan SJ, Yang HP, Hankinson SE, Park Y, Rosner B, Webb PM, Cramer DW, Wentzensen N, Terry KL, Tworoger SS (2013) Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. Cancer Epidemiol Biomarkers Prev 22(3): 429-437.
27. Robbins CL, Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Kulkarni A, Marchbanks PA (2009) Influence of reproductive factors on mortality after epithelial ovarian cancer diagnosis. Cancer Epidemiol Biomarkers Prev 18(7): 2035-2041.
28. Sener SF, Winchester DJ, Winchester DP, Du H, Barrera E, Bilimoria M, Krantz S, Rabbitt S (2009) The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival. Am J Surg 197(3): 403-407.
29. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1): 7-30.
30. Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, Garcia-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PDP, Goode EL, Huntsman DG, Ramus SJ (2013) Hormonereceptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14(9): 853-862.
31. Urban RR, He H, Alfonso R, Hardesty MM (2016) Ovarian cancer outcomes: predictors of early death. Gynecol Oncol 140(2): 474-480.
32. Vitonis AF, Titus-Ernstoff L, Cramer DW (2011) Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy. Obstet Gynecol 117(5): 1042-1050.
33. Wang S, Qiu L, Lang JH, Shen K, Huang HF, Pan LY, Wu M, Yang JX, Guo LN (2013) Prognostic analysis of endometrioid epithelial ovarian cancer with or without endometriosis: a 12-year cohort study of Chinese patients. Am J Obstet Gynecol 209(3): 241.e1-9.
34. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM (2008) Hormone therapy and ovarian cancer: incidence and survival. Cancer Causes Control 19(6): 605-613.
35. Yang L, Klint A, Lambe M, Bellocco R, Riman T, Bergfeldt K, Persson I, Weiderpass E (2008) Predictors of ovarian cancer survival: a populationbased prospective study in Sweden. Int J Cancer 123(3): 672-679.
36. Zhang M, Holman CD (2012) Tubal ligation and survival of ovarian cancer patients. J Obstet Gynaecol Res 38(1): 40-47.